29 articles about Medicines360
Medicines360, a mission-driven nonprofit women's health pharmaceutical organization, announced that its Board of Directors has named Andrea Olariu, MD, PhD as Chief Executive Officer, effective immediately.
7/9/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Medicines360, a global nonprofit women's health pharmaceutical organization, has appointed Tina Raine-Bennett , MD, MPH, FACOG, Chief Executive Officer (CEO), effective immediately, following a broad national search.
Medicines360, a global nonprofit women's health pharmaceutical organization, has appointed Rolf Jansen as the Vice President of Development and Manufacturing. Mr. Jansen is a chemical engineer with more than thirty yea
Medicines360 and Allergan Present Six-Year Clinical Data from Largest Ongoing Phase 3 Study of an Intrauterine System in the U.S.
Six-Year, Multi-Center, Pivotal Clinical Trial Data of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg Presented at 2019 ACOG Meeting
Medicines360, Afaxys Partner to Expand Public Health Access to LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg
Strategic alliance will increase engagement with U.S. public health clinics and their patients about hormonal IUDs (long-acting reversible contraceptives, or LARCs)
Partnership will provide free hormonal IUDs to underserved women across the country
Medicines360 and Allergan Present Five-Year Multi-Center Pivotal Clinical Trial Data of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg at 2018 ACOG Meeting
FDA Acceptance of Medicines360's Filing for supplemental New Drug Application for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg
Allergan plc, (NYSE: AGN) a leading global pharmaceutical company, and Medicines360 today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Medicines360's supplemental New Drug Application (sNDA)
Study Finds Z-CAN Program, Supported by Medicines360, Increased Use of LARCs by Women in Puerto Rico During Zika Outbreak
Medicines360, a global nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, today highlighted a new report published in The Lancet Public Health.
FDA Approves Medicines360's sNDA For LILETTA (Levonorgestrel-Releasing Intrauterine System) 52 Mg To Prevent Pregnancy For Up To Four Years
Medicines360 And Allergan Present Four-Year Multi-Center Pivotal Trial Data Of LILETTA (Levonorgestrel-Releasing Intrauterine System) 52 Mg At The 2017 American College of Obstetricians and Gynecologist Meeting
Medicines360 And Allergan Announce Partnership With Health Centers To Help Address Unintended Pregnancies In Areas Impacted By Zika
Medicines360 And Allergan Announce Study Publication Evaluating Pelvic Infection Risk Following Same-Day Sexually Transmitted Infection Testing And Liletta (Levonorgestrel-Releasing Intrauterine System) 52 Mg Placement
Medicines360 And Population Services International Announce New Partnership To Expand Access To Hormonal IUDs To Women In Africa
Allergan And Medicines360 Announce Launch Of New LILETTA (Levonorgestrel-Releasing Intrauterine System) 52 Mg Single-Handed Inserter
Medicines360 And Allergan Announce Publication Of Levonorgestrel Release Rates Over Five Years With The LILETTA 52 Mg Intrauterine System In 'Contraception'
Allergan And Medicines360 Announce Donation Of Intrauterine Devices (IUD) To The CDC Foundation To Help Address Microcephaly Impact From Zika Virus In Puerto Rico
Medicines360 and Camargo Pharmaceutical Services Gain FDA Approval for Intrauterine Contraceptive Device
Medicines360 Announces New Partnership With Marie Stopes International To Expand Access To Its Hormonal IUD To Women In Kenya, East Africa